Through the joint analysis of TIMER and TCGA databases, we found that DLAT was highly expressed in cholangiocarcinoma (CHOL), esophageal cancer (ESCA), liver hepatocellular carcinoma (LIHC), LUAD, lung squamous cell carcinoma (LUSC), and stomach adenocarcinoma (STAD), and was lowly expressed in BRCA, COAD, HNSC, KIRC, kidney renal papillary cell carcinoma (KIRP), READ, PRAD, and thyroid cancer (THCA) (Figure 1A-B). Here, DLAT is linked to cholangiocarcinoma.